FDA Issues Emergency Use Authorization for Drug for Short-Term Prevention of New World Screwworm in Horses
FDA issued an Emergency Use Authorization (EUA) for Ivermectin Liquid for Horses for short-term prevention of New World screwworm in horses. This is a veterinary drug authorization, not directly impacting human pharmaceutical manufacturing or cGMP compliance. However, it may affect supply chains for ivermectin API and finished dosage forms, particularly for manufacturers supplying both human and veterinary markets.
Aforeworn detected this change in the Pharmaceutical Manufacturing (FDA/DEA) space on July 27, 2026 and published this briefing so affected operators are forewarned rather than caught off guard. It is rated Low urgency. API manufacturers and contract manufacturers producing ivermectin for veterinary use; compounding pharmacies (503B) that may compound ivermectin for equine use; branded and generic drug makers with ivermectin products for human use (potential supply diversion). should confirm how it applies to their specific situation before acting. There is a time constraint attached: Ongoing; no immediate deadline but should be monitored as the EUA is in effect.. Acting after that point can mean penalties, a lapsed licence, or lost eligibility — exactly the kind of surprise Aforeworn exists to prevent. Aforeworn monitors Pharmaceutical Manufacturing (FDA/DEA) continuously and turns every detected change into a plain-English briefing like this one, so you always know first. Forewarned is forearmed.
What changed
FDA authorized emergency use of ivermectin oral solution for horses for screwworm prevention, which may increase demand for ivermectin API and finished product, potentially straining supply for human indications.
Who it affects
API manufacturers and contract manufacturers producing ivermectin for veterinary use; compounding pharmacies (503B) that may compound ivermectin for equine use; branded and generic drug makers with ivermectin products for human use (potential supply diversion).
What you must do
Monitor ivermectin supply chain for potential shortages or diversion; ensure compliance with existing cGMP and FDA regulations for any products manufactured under this EUA; compounding pharmacies should verify they are not compounding from unauthorized sources.
Deadline
Ongoing; no immediate deadline but should be monitored as the EUA is in effect.
Never miss a change like this again
Aforeworn watches Pharmaceutical Manufacturing (FDA/DEA) around the clock and alerts you the moment a rule moves — with a plain-English brief on what to do.
Start your free trialRelated changes in Pharmaceutical Manufacturing (FDA/DEA)
- Continuing the Suspension of Duty-Free De Minimis Treatment for All Countries
- FDA Issues Draft Guidance to Cut Unnecessary Animal Testing for Cancer Drugs
- FDA Issues Draft Guidance to Help Accelerate Cell and Gene Therapies for Patients
- FDA Expands Sunscreen Options for the First Time in 20 Years
- FDA Issues Emergency Use Authorization for Generic Over-the-Counter Drug to Treat New World Screwworm in Dogs and Cats